Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza investigational vaccine GSK2340274A · 1 trial · 1 indication
Titers are presented as geometric mean titers (GMTs).
A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10.
A seropositive subject was defined as a subject whose serum antibody titer was greater than or equal to (≥) 1:10.
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer smaller than (\<) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer.
A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition (HI) titer ≥ 1:40.
The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0.
| Arm | Type | Description |
|---|---|---|
| GSK2340274A GROUP | EXPERIMENTAL | Healthy subjects, aged 20 to 64 years, male and female, received 2 doses of GSK2340274A vaccine, injected intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21. |
| Name | Type | Description |
|---|---|---|
| Influenza investigational vaccine GSK2340274A | BIOLOGICAL | Two intramuscular injections on Day 0 and Day 21, respectively |
Inclusion Criteria: * Japanese male and female adults 20 to 64 years of age at time of the first vaccination, inclusive. * Good general health as assessed by medical history and physical examination * Subjects who the investigator believes that they can and will comply with the requirements of the ...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
GSK2340274A is an investigational influenza vaccine developed by GSK plc. It is a Phase 2 vaccine candidate studied for the prevention of influenza, including H1N1 influenza. It has been evaluated in a single completed clinical trial conducted in Japan.
GSK2340274A is being studied for use against influenza. Its completed Phase 2 trial evaluated immunogenicity and safety of the investigational influenza vaccine in the context of H1N1. It is not an approved product and remains an investigational vaccine candidate.
GSK2340274A is developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 2 study of the vaccine candidate in Japan.
GSK2340274A is in Phase 2 development. Its only listed trial, NCT00989612, is a completed Phase 2 study. The vaccine is investigational and has not been established as an approved product.
GSK2340274A has been studied in one clinical trial, NCT00989612, titled Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1). That Phase 2 trial is completed, enrolled 100 participants, was conducted in Japan, and included healthy volunteers aged 20 years and older.
The Phase 2 trial of GSK2340274A, NCT00989612, was an uncontrolled study and was not double blind. It enrolled 100 participants in Japan and assessed immunogenicity and safety of the investigational H1N1 influenza vaccine in healthy volunteers.